AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01420549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
Description: Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
Study NCT02072772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free group treatment
Description: See Arm Description
Study NCT02072772 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: See Arm Description
Study NCT03672630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]
Study NCT00111579 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAIV-T
Description: A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
Study NCT00111579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TIV
Description: A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
Study NCT03082989 — intervention group
Intervention type: DEVICE
Intervention: fractional flow reserve performed
Description: assessing fractional flow reserve to drive revascularization
Study NCT03082989 — intervention group
Intervention type: OTHER
Intervention: fractional flow reserve not performed
Description: description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
Study NCT02270684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StepRite
Description: The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
Study NCT00966810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect > 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
Study NCT01954069 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Semi-quantitative pregnancy test
Study NCT01369849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01369849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT01369849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01369849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00502632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase and Dornase alfa
Description: Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days
Study NCT00502632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Urokinase
Description: Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* 25ml normal saline, twice daily for 4 days
Study NCT04568317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Depression
Description: This is a 7-module internet-based CBT program. The structure and content of the modules follow evidence-based CBT principles; they are structured to incorporate quizzes, videos, psychoeducational content and interactive tools, personalised homework suggestions and summaries. One of the interactive tools is the mood monitor, where users are encouraged to monitor their mood and reflect on several factors that might had influenced it. Clients are allocated to a psychological wellbeing practitioner (PWP). The PWP is responsible for monitoring and guiding the client's progress throughout the intervention. Over the course of the 8 week supported intervention period, on 6 separate occasions the PWP will review participants progress, leaving feedback for them and responding to the work they have completed. The basic share level allows PWP is to view users' goals for the week, key messages and progress points. Each PWP will provide post-session feedback of between 10 and 15 minutes per session.
Study NCT04568317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Space from Depression
Description: This is a 7-module internet-based CBT program. The structure and content of the modules follow evidence-based CBT principles; they are structured to incorporate quizzes, videos, psychoeducational content and interactive tools, personalised homework suggestions and summaries. One of the interactive tools is the mood monitor, where users are encouraged to monitor their mood and reflect on several factors that might had influenced it. Clients are allocated to a psychological wellbeing practitioner (PWP). The PWP is responsible for monitoring and guiding the client's progress throughout the intervention. Over the course of the 8 week supported intervention period, on 6 separate occasions the PWP will review participants progress, leaving feedback for them and responding to the work they have completed. The basic share level allows PWP is to view users' goals for the week, key messages and progress points. Each PWP will provide post-session feedback of between 10 and 15 minutes per session.
Study NCT04568317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mood Monitor watch app
Description: The Mood Monitor watch app will allow in-the-moment self-report of patients' mood and automated monitoring of their sleep and activity level. This data will be integrated into the existing Mood Monitor tool within the participant's Space from Depression program. During the intervention, prompts to record mood data will appear on the watch app; participants will be encourage to choose the frequency and time ranges to receive prompts. The watch app main screen will provide a daily and weekly visualisation of participant's mood, bedtime, hours slept and steps count, and visual cues on their progress. Participants will receive encouragement prompts to reward frequent and consistent self-report of mood over time and a good sleep hygiene. Finally, the app Tips to Stay Well feature will allow participants to go through a list of lifestyle-related tips extracted from the Space from Depression program.
Study NCT03499821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDOF ICL
Description: The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
Study NCT02001675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging (MRI)
Study NCT02001675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 31-phosphorous magnetic resonance spectroscopy (MRS-P31)
Study NCT03216278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR 5/500mg
Description: Tablets for oral administration, once daily, once per treatment period
Study NCT03216278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin/metformin XR 5/500 mg
Description: Tablets for oral administration, once daily, once per treatment period
Study NCT03216278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin/metformin XR 5/500mg
Description: Tablets for oral administration, once daily, once per treatment period
Study NCT03216278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR 10/1000mg
Description: Tablets for oral administration, once daily, once per treatment period
Study NCT03216278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin/metformin XR 10/1000mg
Description: Tablets for oral administration, once daily, once per treatment period
Study NCT04039191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS education
Description: Patients will receive additional educational SMS messages post-operatively
Study NCT04039191 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SMS survey
Description: Patients will receive survey questions about post-operative pain and opioid use but no education
Study NCT04260659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride [Dexdor]
Description: Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
Study NCT04260659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil [Ultiva]
Description: Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
Study NCT04260659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine [Ketalar]
Description: Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
Study NCT04260659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine [Xylocaine 2%]
Description: Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
Study NCT04260659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]
Description: Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
Study NCT04260659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl [Fentanyl WZF]
Description: Rescue dosis of 100 mcg iv will be administered if hypertension > 140/90 mmHg or tachycardia > 120min occurs. If necessary rescue dosis may be repeated.
Study NCT03103906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream (Test product)
Description: Moisturizing cream with SPF (Sun protecting factor) 20
Study NCT03103906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleanser (Reference Product)
Description: Moisturizing facial cleanser
Study NCT03103906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cleanser (Reference Product)
Description: Moisturizing facial cleanser
Study NCT03672630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol 25 mg/kg \[MYAMBUTOL\]
Study NCT03672630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Rifampin 600 MG \[RIFADIN\]
Study NCT02530177 — intervention group
Intervention type: OTHER
Intervention: Clinical Assessments
Study NCT03103906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen (Reference Product)
Description: SPF 50 sunscreen
Study NCT03103906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen (Reference Product)
Description: SPF 50 sunscreen
Study NCT02545842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT01023438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy for assisted uptitration
Description: Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
Study NCT01023438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
Study NCT03608995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Premaquick (Diagnostic test)
Description: PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes.
Study NCT03608995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quikcheck fFN ™
Description: - The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
Study NCT04944407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LHP
Description: A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
Study NCT04944407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MM
Description: The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
Study NCT00821184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vesicare (solifenacin)
Description: 5mg po qd
Study NCT00821184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vesicare (solifenacin) plus behavioral modification
Description: 5 mg dose po once daily plus behavioral modification
Study NCT01850836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Study NCT01850836 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Study NCT03204565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap
Description: coronally advanced flap alone (CAF- control)
Study NCT01806636 — intervention group
Intervention type: DEVICE
Intervention: PneumRx Coil System
Study NCT04224818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual trigger
Description: Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)
Study NCT04224818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG (standard)
Description: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)
Study NCT03204565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced flap
Description: coronally advanced flap alone (CAF- control)
Study NCT03204565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
Study NCT01402479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: ramipril 2.5mg twice a day
Study NCT02703246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal morcellation
Description: patients will be randomized to receive abdominal morcellation
Study NCT02703246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal morcellation
Description: patients will be randomized to receive vaginal morcellation
Study NCT02530177 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Study NCT02567214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultibro®
Description: The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
Study NCT02567214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva®
Description: The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
Study NCT02530177 — intervention group
Intervention type: OTHER
Intervention: Saliva sample
Description: (only once, preferably at baseline)
Study NCT00701155 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
Study NCT01892449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prolonged inspiratory to expiratory (I:E) ratio (1:1)
Description: 80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.
Study NCT01892449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional I:E ratio (1:2)
Description: 80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
Study NCT03555188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron is a highly selective receptor antagonist (5-HT3RA)
Study NCT03555188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron is a highly selective receptor antagonist (5-HT3RA)
Study NCT00594204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline tartrate (CP-526, 555-18)
Description: 1 mg twice a day for 12 weeks, starting with a 1-week titration period.
Study NCT00594204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo 1 tablet twice a day for 12 weeks
Study NCT01975233 — intervention group
Intervention type: DEVICE
Intervention: WEB Aneurysm Embolization System
Description: WEB Aneurysm Embolization System
Study NCT04407455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Karaduman Chewing Performance Scale
Description: For chewing evaluation, children will be asked to bite and chew a standardized biscuit. Each chewing evaluation will be scored according to the KCPS.
Study NCT04883476 — intervention group
Intervention type: OTHER
Intervention: Observation study only
Study NCT01049503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fluoride and conventional dentifrices with different pH
Description: Comparison of different dentifrice fluoride concentrations and pH on caries control
Study NCT00726596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
Study NCT02788604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Summary of psychosocial risk factors
Description: The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.
Study NCT02788604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
Study NCT02234128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toronto EVLP System™
Description: Extending preservation and assessment time of donor lungs using the Toronto EVLP System